SPTX Company Profile and Key Details

Average 10-day trading volume of 149.41 thousand shares is in line with the 3-month average of 164.57 thousand, indicating normal recent market interest.

Seaport Therapeutics, Inc. Common Stock has 53.53 million shares outstanding. The public float is 28.29 million shares, elevated short interest at 3.89% of float. This equals 1.98 million shares. The short ratio is 7.71 days. Institutional investors hold 108.75% of the float. Insiders own 35.08%.

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $30.00. The high target offers 129.89% upside. The low target suggests 37.93% downside. The mean target is $40.33. This offers 85.43% upside. Seaport Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 03, 2026, missed forecasts by 186.92%. The prior quarter beat by 93.78%. Over the last six quarters, Apple has recorded several small beats. These include 93.78% in June 08, 2026.

Seaport Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.06. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Seaport Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.72%, with price expected at $25.17 by September 22, 2026, within a range of $23.94 to $26.40 3-Month Outlook: Projected rise of 0.14%, reaching $21.78 by December 07, 2026, with a range of $21.55 to $22.01. 1-Year Outlook: Projected gain of 469.43%, with price at $123.85 by September 08, 2027, within a range of $123.56 to $124.13.

Seaport Therapeutics, Inc. Common Stock (NASDAQ:SPTX) closed at $21.75 USD, losing -$2.31 (-9.60%) from the previous close of $24.06. The stock is currently mid-range between its 52-week high and low $14.85 and $28.38. With a market capitalization of about $1.16 billion, Seaport Therapeutics, Inc. Common Stock is classified as a small-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 162.54 thousand shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Seaport Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daphne Zohar, the company employs approximately 58 people and listed since May 01, 2026. Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions.

Valuation shows Seaport Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -13.84. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.33, suggesting 85.43% upside. Our AI forecast model points to short-term strength (15.72% over two weeks), a medium-term rise (0.14% over three months), and a longer-term gain (469.43% over one year), with expected trading ranges indicating moderate volatility.

Seaport Therapeutics, Inc. Common Stock trades at a P/E ratio of -13.84, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.89 suggesting the stock is closer to book value. The P/FCF stands at -26.39, also below market averages.